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in orthopedics such as calcium phosphate (Fig. 1). 
The focus of the infection in the bone treated with AMP 
mixed with carrier was eradicated much more effectively 
then the focus treated with antibiotics such as vancomycin or 
gentamicin mixed with the same carrier. Furthermore, AMPs 
incorporated into model implant made from poly-methylmet-
hacrylate based bone cement prevented the formation of the 
bacterial biofilm on its surface after the implant was inserted 
inside the infected bone.
Fig. 1. Infected spongy part of the bone sample filled with 
a peptide mixed with local carrier (a, b), local carrier alone 
(c), and local carrier loaded with antibiotic (d).
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Gastrointestinal peptides are mainly involved in the re-
gulation of food intake and energy homeostasis and have 
emerged as a promising target for new obesity treatments.
[1] However, the food regulation system is tightly regulated 
in interconnected pathways where redundancies can lead to 
poor efficacy and drug tolerance.[2] Ghrelin and Y2 receptors 
both play a central role in appetite regulation inducing oppo-
site effects.[3,4] The Y2 receptor is involved in the short-term 
satiety signaling while the ghrelin receptor mediates hunger, 
promotes weight gain and stimulates energy homeostasis.
In this context, we previously developed a rational multi-
targeting approach to simultaneously target the ghrelin and 
Y2 receptors and we designed a dual peptide that showed a 
dual activity in vitro but a moderate stability in vivo.[5] The 
simultaneous targeting of ghrelin and Y2 receptors was based 
on the co-localisation of both receptors on the same neuronal 
population, the NPY/AgRP neurons, in the arcuate nucleus 
of hypothalamus.
In order to increase the stability of the dual peptide, we 
recently developed new derivatives using two ligation 
techniques: the Copper-catalysed Azide-Alkyne Cycloadditi-
on (CuAAC) and the oxime ligation. The stability of the dual 
peptides has been evaluated in vitro in human blood plasma 
and liver.
[1]. Troke, R. C., Tan, T. M. & Bloom, S. R. The future role of gut hormones in the 
treatment of obesity. Ther Adv Chronic Dis 5, 4-14 (2014).
[2]. Bloom, S. R. et al. The obesity epidemic: pharmacological challenges. Mol. 
Interv. 8, 82-98 (2008).
[3]. Leite-Moreira, A. F. & Soares, J.-B. Physiological, pathological and potential 
therapeutic roles of ghrelin. Drug Discovery Today 12, 276-288 (2007).
[4]. Karra, E., Chandarana, K. & Batterham, R. L. The role of peptide YY in appetite 
regulation and obesity. The Journal of Physiology 587, 19-25 (2009).
[5]. Kilian, T.-M. et al. Rational Design of Dual Peptides Targeting Ghrelin and Y2 
Receptors to Regulate Food Intake and Body Weight. J. Med. Chem. 58, 4180-
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The number of bacterial strains resistant to current classes 
of antibiotics is increasing and has led some to warn that we 
are approaching an “antibiotic apocalypse.” Therefore, there 
is an increasingly urgent need for new structurally and me-
chanistically distinct classes of antibiotics. The tridecaptins 
are linear, non-ribosomally synthesized peptides produced 
by Bacillus and Paenibacillus species. Although they have 
been known for decades, their antimicrobial activity was left 
mostly unexplored until their serendipitous re-discovery by 
our group.1-3 In particular, analogues of tridecaptin A1 (TriA1) 
show selective activity against Gram-negative bacteria, in-
cluding against multidrug resistant Klebsiella pneumoniae 
both in vitro and in vivo (mouse model).4-6 Furthermore, 
no persistent resistance develops against Escherichia coli 
exposed to low concentrations of octyl-tridecaptin A1 (Oct-
TriA1) over a one-month period. Our studies have shown 
that TriA1 selectively binds to the Gram-negative analogue 
of peptidoglycan precursor lipid II. Nuclear Magnetic Reso-
nance (NMR) and molecular docking studies were used to 
determine the NMR solution structure of the Oct-TriA1:lipid 
II complex, identifying a new lipid II binding motif for an 
antimicrobial peptide. Our studies suggest that TriA1 exerts 
its bactericidal effect against Gram-negative bacteria through 
disruption of the proton motive force at the inner-membrane. 
Furthermore, we have used in vitro assays to show that the 
presence of Gram-negative lipid II in artificial membranes 
significantly accelerates the disruption of a proton gradient. 
Based on our studies, we believe tridecaptin A1 could be an 
excellent antibiotic candidate.
[1] J. Shoji, H. Hindo, R. Sakazaki, T. Kato, Y. Wakisaka, M. Mayama, S. Matsuura, 
H. Miwa, J. Antibiot. 31, 646 (1978)
[2] C.T. Lohans, M.J. van Belkum, S.A. Cochrane, Z. Huang, C.S. Sit, L.M. McMullen, 
J.C. Vederas, ChemBioChem 15, 243 (2014)
[3] S.A. Cochrane, C.T. Lohans, M.J. van Belkum, M.A. Bels, J.C. Vederas, Org. 
Biomol. Chem. 13, 6073 (2015)
[4] S.A. Cochrane, C.T. Lohans, J.R. Brandelli, G. Mulvey, G.D. Armstrong, J.C. 
Vederas, J. Med. Chem. 57, 1127 (2014)
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Kyotorphin (KTP) is an endogenous analgesic neuropep-
tide (L-Tyr-L-Arg) with limited ability to cross the blood-
brain barrier (BBB) after systemic administration.1,2 This 
behaviour, which narrows its pharmacological applications, 
has been ascribed to both insufficient lipophilicity and su-
sceptibility to enzymatic degradation.2 With the aim of in-
creasing the lipophilicity of KTP, several new derivatives 
have been prepared upon chemical modification of the basic 
structure. The kyotorphin analogue KTP-amide (KTP-NH2) 
presents improved lipophilicity and analgesic activity follo-
wing administration in animal models.3 Apart from the ability 
to cross the BBB, other relevant issues in the development of 
drugs for the central nervous system are related with the as-
sessment of toxicity and determination of the biological fate. 
Thus, with the aim of addressing such issues, in this commu-
nication, we will report on the radiolabelling of KTP-NH2 
with 125I- as well as on the assessment of the interaction of 
the resulting radioiodinated peptide with the BBB through 
permeation studies in bEnd.3 cell lines. We will also descri-
be the biodistribution studies of the radioiodinated peptide in 
Sprague-Dawley male rats. In addition, to check whether the 
incorporation of iodine into the tyrosyl residue of KTP-NH2 
would affect its analgesic efficacy, KTP-NH2 was iodinated 
with “cold”, non-radioactive, iodide and the analgesic effi-
cacy of the resulting mono-iodinated (MIK) and di-iodinated 
(DIK) peptides was evaluated in acute pain models. The main 
conclusion drawn from these studies is that although the ra-
dioiodinated peptide could translocate the cellular model of 
the BBB, the accumulation of that species in the brain was 
not relevant. Significant accumulation of 125I was found in the 
thyroid, probably reflecting the hydrolysis of the iodine-ty-
rosine bond by liver deiodinases. The analgesic activity of 
mono- and di-iodinated KTP-NH2, evaluated by the hot plate 
assay, showed a delayed peak of maximal efficacy compared 
to non-iodinated KTP-NH2 (30 vs. 15 minutes). Overall, the 
peripheral effects of the peptides cannot be excluded.
1 - H. Takagi, H. Shiomi, H. Ueda and H. Amano, Nature 1979, 282, 410.
2 - P. Chen, N. Bodor, W. M. Wu and L. Prokai, J. Med. Chem. 1998, 41, 3773.
3 - S. C. Lopes, A. Fedorov and M. A. Castanho, ChemMedChem 2006, 1, 723.
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Albicidin is produced by the sugarcane pathogenic bac-
terium Xanthomonas albilineans and is a potent antibiotic 
specifically targeting the bacterial DNA gyrase with an IC
50
 
value in the nanomolar range. The structure of albicidin, 
which has remained unsolved for more than three decades 
since its first description, has been solved by a combination 
of extensive NMR and HR-MS/MS experiments. An inherent 
problem for the structure elucidation was the low amount of 
the albicidin production in cell culture. The low production 
forced us to cultivate several hundred liters in order to purify 
a few milligrams required for NMR experiments. In compa-
rison, LC-HR-MS/MS has the great advantage of several or-
ders of magnitude and high sensitivity. Thus, this approach 
requires much less material. But more importantly, purifica-
tion of compounds is not necessary for structural analysis. 
Due to the application of targeted LC-MS/MS experiments, 
we were able to propose the structure of N-terminal carba-
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moylated and b-methoxylated albicidin derivatives. Both of 
them are currently chemically synthesized and studied in a 
medicinal chemistry campaign. In order to search for more 
pharmaceutically relevant albicidin derivatives, we applied 
non-targeted LC-HR-MS/MS approaches combined with 
mass spectral networking, a recently introduced approach 
for non-targeted MS/MS data-analysis. However, as for the 
structural elucidation of albicidin, the even lower concentra-
ted derivatives resulted in difficulties to obtain useful MS/
MS spectra. Since we typically operate the mass spectrome-
ter in data-dependent acquisition mode (DDA), it inherently 
selects high abundant compounds of cell extracts for MS/
MS scans and possibly ignore low abundant compounds. The 
same goes for the network analysis which is based on simila-
rity of MS/MS spectra and may not take potential ion species 
into account. To overcome this problem, we implemented 
a bioactivity-guided fractionation by solid phase extraction 
and semi-preparative HPLC. Fractions with antibacterial ac-
tivity were subsequently submitted to several LC-MS/MS 
runs in DDA mode with shifted survey scan windows (stit-
ched DDA). Besides the increased amount of MS/MS events 
per mass range, narrowing down the m/z range of the survey 
scan also increased the dynamic range of the orbitrap analy-
zer, which enabled us to significantly increase the method’s 
sensitivity. Finally, we were able to detect a whole series of 
new albicidin derivatives and to propose their structures ba-
sed on exact mass determination and MS/MS fragmentation 
patterns. These new compounds provide great opportunities 
in lead optimization of albicidin as a new anti-infective drug. 
Apart from the pharmaceutical relevance, some of the identi-
fied by-products give us important insights into the formation 
of albicidin and its intriguing biosynthetic machinery. 
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Diseases such as diabetes and obesity have become major 
health concerns worldwide. To address this issue, our group 
is attempting to contribute through a focus on neuromedin 
U (NMU), a highly conserved neuropeptide regulator of 
feeding, energy homeostasis and glycemic control. It exerts 
its biological effects via two G protein-coupled receptors, 
NMUR1 and NMUR2. NMUR1 is mostly found in the peri-
phery whereas NMUR2 is most abundant in the central ner-
vous system. Both central and pheripheral administration of 
the peptide reduce food intake and body weight in rodents. 
The anorexigenic effect of NMU renders NMUR agonists at-
tractive as potential therapeutics in the treatment of diabetes 
and obesity [1].
NMU-8 (H-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2), a 
natural occurring fragment of NMU, is taken as lead mo-
lecule for the synthesis of novel analogues. A first batch of 
analogues is prepared on basis of the available structure-ac-
tivity relationships described in the literature [2,3]. Mainly 
two types of modifications were initially performed, namely 
chirality switches and the introduction of different N-cap-
ping groups. In a second set of NMU-ligands, more advan-
ced modifications are performed, such as the introduction of 
unnatural/constrained amino acids or N-alkylated glycines 
(‘peptoid’) analogues in the NMU-sequence. A third genera-
tion of compounds was synthesized and contains analogues 
in which the most promising modifications of the previous 
generations were combined. The in vitro characterization of 
these peptides has been performed by an inositol phosphate 
accumulation assay. Additionally, the plasma stability of the-
se analogues has been investigated.
The results of the in vitro characterization present the 
discovery of high potency agonists. Compared to NMU-8, 
more active agonists on both NMURs were discovered. Our 
experiments revealed, for instance, that acetylation of the 
N-terminus leads in general to an increase of activity. When 
replacing Tyr1 by 7-OH-Tic or Dmt, extremely potent ago-
nists for both receptors were obtained as well. Moreover, an 
improved plasma stability of these compounds is observed. 
The replacement of Phe4 by 7-OH-Tic, Dmt, Oic, 1’Nal or 
2’Nal leads to ligands with a comparable activity to NMU-8, 
but an increased plasma stability emerged. The most promi-
sing ligands were tested in an in vivo model to study their 
effect on food intake, and promising results were obtained.
[1] Dalbøge et al, Peptides. 2015; 69: 56-65 
[2] Hashimoto et al, Chem Pharm Bull. 1991; 39(9): 2319-22 
[3] Takayama et al, Med Chem. 2014; 57(15): 6583-93
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The translocator protein (TSPO, 18 kDa) plays an import-
ant role for the synthesis of neurosteroids by promoting the 
transport of cholesterol from the outer to the inner mitochon-
drial membrane, which is the rate-limiting step in neuroste-
roidogenesis. Stimulation of TSPO by appropriate ligands 
increases the level of neurosteroids [1].
The present study describes design, synthesis and inves-
tigation of anxiolytic-like effects of novel dipeptide TSPO 
ligand, originally designed on the basis of drug-based peptide 
design method [2] using Alpidem as non-peptide prototype. 
It is known that Alpidem demonstrates anxiolytic activity 
[3] and its structure contains all the necessary TSPO ligands 
pharmacophore elements. Due to these arguments the dipep-
tide N-carbobenzoxy-L-tryptophanyl-L-isoleucine amide 
(GD-23) was designed as putative ligand.
Then we used semi-rigid docking with AutoDock Vina 
1.1.2 to confirm the similarity of structures of Alpidem and 
dipeptide GD-23. The conformations that we selected from 
AutoDock Vina 1.1.2 demonstrated the minimum strain of 
the valent angles and bonds.
The anxiolytic activities were investigated in Balb/C mice 
using the illuminated open-field test [4] and elevated plus-
maze test in CD-1 mice. The activating effect on locomotor 
activity in mice was taken as a measure of the anxiolytic ac-
tivity of compound. GD-23 in the dosage range 0.05-1.0 mg/
kg significantly (p<0.005) increased total locomotor activity 
of mice compared with control groups. GD-23 significantly 
(p <0.001) increased the percentage of time spent in the open 
arms of the maze in the dose range of 0.1-1.0 mg/kg. Anxio-
lytic effect of GD-23 was abolished by PK11195, a specific 
TSPO antagonist. It was found that by pretreatment with tri-
lostane, a selective inhibitor of 3β-HSD, or finasteride, a se-
lective 5α-reductase inhibitor, anxiolytic effect of GD-23 was 
not registered. Results were evaluated as the ratio of the time 
spent in the open arms of maze to the total residence time of 
the animals in the open and closed arms. The obtained results 
demonstrate that the anxiolytic effect is mediated by inter-
action of the compound GD-23 with TSPO receptor. Hence 
GD-23 can provide a basis for a new peptide class of fast 
anxiolytics without side effects of benzodiazepines.
This work was supported by the Basic Research Program of the 
Presidium of the Russian Academy of Sciences (The project “Design, 
synthesis and pharmacological properties of the original ligands of 
the mitochondrial protein TSPO»).
:[1] Nothdurfter C. et al., J. Neuroendocrinol., 2012, 24 (1), 82-92
[2] Gudasheva T.A. et al., J. Med. Chem., 1998, 41(3), 284-290
[3] Cappelli A. et.al., Bioorg. & Med. Chem., 2008, 16, 3428-3437
[4] Seredenin S.B. et al., Biull .Eksp. Biol. Med. (Russia), 1979, 88, №1, 
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Peptide-based vaccines would appear as the ideal alterna-
tive to conventional (e.g., inactivated whole-virus) vaccines, 
because they are safe (no infectious agent involved), versatile 
(readily adaptable to emergent outbreaks) and cost-effective 
(reliable, reproducible production and scale-up by chemical 
synthesis; simple storage and transport). These advantages 
are however offset by problems such as the difficulty in de-
finition and chemical reproduction of epitopes, the usually 
low immunogenicity of peptides, or the often intricate relati-
on between host-pathogen interaction and immune response, 
all of which partly explains why only a handful of peptide 
vaccines have attained therapeutic status.
Among the different pathogens targeted by peptide vac-
cines, foot-and-mouth disease virus (FMDV), arguably the 
economically most devastating animal disease worldwide, 
has received considerable attention. We have recently de-
scribed vaccine candidates, generically known as BnT, con-
sisting of a T-cell epitope branching out via a Lys tree into 
multiple (n= 2, 4) copies of a B-cell epitope.1,2 This particu-
lar arrangement of B and T epitopes on a single molecular 
platform is shown to confer full protection against FMDV 
challenge in both swine and cattle.3 Our presentation will 
illustrate various important aspects in the development of 
this synthetic vaccine, particularly issues such as epitope 
orientation and multiplicity,4 chemical ligation methods5 or 
adjuvanticity as well as provide insights on the uptake of 
the peptide by immune cells and on its in vivo localization. 
1. Cubillos C, de la Torre BG, Jakab A, Clementi G, Borras E, Bárcena 
J, Andreu D, Sobrino F, Blanco E, J. Virol. 2008, 82, 7223-7230. 
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